List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7839903/publications.pdf Version: 2024-02-01



ADDIAN | HADDIS

#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Hypoxia — a key regulatory factor in tumour growth. Nature Reviews Cancer, 2002, 2, 38-47.	28.4	4,590
3	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
4	Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis. Journal of the National Cancer Institute, 2006, 98, 262-272.	6.3	1,824
5	Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10393-10398.	7.1	1,796
6	Detection of elevated levels of tumourâ€associated microRNAs in serum of patients with diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2008, 141, 672-675.	2.5	1,570
7	The Expression and Distribution of the Hypoxia-Inducible Factors HIF-1α and HIF-2α in Normal Human Tissues, Cancers, and Tumor-Associated Macrophages. American Journal of Pathology, 2000, 157, 411-421.	3.8	1,191
8	Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer. Journal of the National Cancer Institute, 2006, 98, 1183-1192.	6.3	1,128
9	Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 780-788.	3.3	1,068
10	Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse. Journal of Clinical Oncology, 2006, 24, 5373-5380.	1.6	997
11	Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-inducible Factor. Journal of Biological Chemistry, 2004, 279, 38458-38465.	3.4	918
12	Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma. Molecular and Cellular Biology, 2005, 25, 5675-5686.	2.3	847
13	Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series. Clinical Cancer Research, 2007, 13, 3207-3214.	7.0	839
14	How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature, 2012, 491, 364-373.	27.8	800
15	Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 2017, 14, 169-186.	27.6	792
16	Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade. Journal of Clinical Oncology, 2007, 25, 1239-1246.	1.6	711
17	Antiangiogenic therapy in oncology: current status and future directions. Lancet, The, 2016, 388, 518-529.	13.7	663
18	bcl-2 Protein in Non-Small-Cell Lung Carcinoma. New England Journal of Medicine, 1993, 329, 690-694.	27.0	652

#	Article	IF	CITATIONS
19	hsa-miR-210 Is Induced by Hypoxia and Is an Independent Prognostic Factor in Breast Cancer. Clinical Cancer Research, 2008, 14, 1340-1348.	7.0	617
20	Acetyl-CoA Synthetase 2 Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress. Cancer Cell, 2015, 27, 57-71.	16.8	596
21	Advances in Hypoxia-Inducible Factor Biology. Cell Metabolism, 2018, 27, 281-298.	16.2	571
22	Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nature Medicine, 2011, 17, 1101-1108.	30.7	552
23	Fatty Acid Uptake and Lipid Storage Induced by HIF-11± Contribute to Cell Growth and Survival after Hypoxia-Reoxygenation. Cell Reports, 2014, 9, 349-365.	6.4	498
24	Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer and Metastasis Reviews, 2007, 26, 299-310.	5.9	470
25	HIF activation identifies early lesions in VHL kidneys. Cancer Cell, 2002, 1, 459-468.	16.8	456
26	NKT Cells Enhance CD4+ and CD8+ T Cell Responses to Soluble Antigen In Vivo through Direct Interaction with Dendritic Cells. Journal of Immunology, 2003, 171, 5140-5147.	0.8	445
27	Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis, 2018, 21, 425-532.	7.2	429
28	Activating transcription factor 4. International Journal of Biochemistry and Cell Biology, 2008, 40, 14-21.	2.8	419
29	The chemistry, physiology and pathology of pH in cancer. Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369, 20130099.	4.0	412
30	miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors. Molecular Cell, 2011, 41, 210-220.	9.7	409
31	Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma. Journal of Clinical Oncology, 2001, 19, 3660-3668.	1.6	406
32	Comparison of Metabolic Pathways between Cancer Cells and Stromal Cells in Colorectal Carcinomas: a Metabolic Survival Role for Tumor-Associated Stroma. Cancer Research, 2006, 66, 632-637.	0.9	406
33	Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis. Journal of Pathology, 1995, 177, 275-283.	4.5	396
34	Targeting gene expression to hypoxic tumor cells. Nature Medicine, 1997, 3, 515-520.	30.7	362
35	Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2008, 14, 7917-7923.	7.0	361
36	Relation of a Hypoxia Metagene Derived from Head and Neck Cancer to Prognosis of Multiple Cancers. Cancer Research, 2007, 67, 3441-3449.	0.9	349

#	Article	IF	CITATIONS
37	New mechanism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes. Blood, 2010, 116, 2385-2394.	1.4	344
38	The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer, 1990, 65, 1619-1625.	4.1	336
39	HIF-1α Induces Genetic Instability by Transcriptionally Downregulating MutSα Expression. Molecular Cell, 2005, 17, 793-803.	9.7	332
40	Tumor-associated macrophages in breast cancer. Journal of Mammary Gland Biology and Neoplasia, 2002, 7, 177-189.	2.7	330
41	Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood, 2006, 107, 931-939.	1.4	327
42	Up-regulation of Delta-like 4 Ligand in Human Tumor Vasculature and the Role of Basal Expression in Endothelial Cell Function. Cancer Research, 2005, 65, 8690-8697.	0.9	323
43	Glucose Utilization via Glycogen Phosphorylase Sustains Proliferation and Prevents Premature Senescence in Cancer Cells. Cell Metabolism, 2012, 16, 751-764.	16.2	320
44	Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2002, 53, 1192-1202.	0.8	311
45	elF4E expression in tumors: its possible role in progression of malignancies. International Journal of Biochemistry and Cell Biology, 1999, 31, 59-72.	2.8	308
46	Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Research, 2003, 63, 6130-4.	0.9	306
47	bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. British Journal of Cancer, 1994, 69, 135-139.	6.4	301
48	Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Research, 2002, 62, 1315-20.	0.9	294
49	Distinct MicroRNA Alterations Characterize High- and Low-Grade Bladder Cancer. Cancer Research, 2009, 69, 8472-8481.	0.9	291
50	Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncology, The, 2010, 11, 1172-1183.	10.7	290
51	microRNA-Associated Progression Pathways and Potential Therapeutic Targets Identified by Integrated mRNA and microRNA Expression Profiling in Breast Cancer. Cancer Research, 2011, 71, 5635-5645.	0.9	285
52	A Five-Gene Molecular Grade Index and <i>HOXB13:IL17BR</i> Are Complementary Prognostic Factors in Early Stage Breast Cancer. Clinical Cancer Research, 2008, 14, 2601-2608.	7.0	283
53	Delta-like 4 Notch Ligand Regulates Tumor Angiogenesis, Improves Tumor Vascular Function, and Promotes Tumor Growth <i>In vivo</i> . Cancer Research, 2007, 67, 11244-11253.	0.9	282
54	Endogenous Markers of Two Separate Hypoxia Response Pathways (hypoxia inducible factor 2 alpha) Tj ETQq0	0 0 rgBT /0	Overlock 10 7

Recruited in the CHART Randomized Trial. Journal of Clinical Oncology, 2006, 24, 727-735.

#	Article	IF	CITATIONS
55	MicroRNA-210 Regulates Mitochondrial Free Radical Response to Hypoxia and Krebs Cycle in Cancer Cells by Targeting Iron Sulfur Cluster Protein ISCU. PLoS ONE, 2010, 5, e10345.	2.5	276
56	Role of Carbonic Anhydrase IX in Human Tumor Cell Growth, Survival, and Invasion. Cancer Research, 2004, 64, 6160-6165.	0.9	273
57	Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Research, 2003, 63, 1764-8.	0.9	273
58	Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia. Blood, 2009, 114, 844-859.	1.4	271
59	Recurrent PTPRB and PLCC1 mutations in angiosarcoma. Nature Genetics, 2014, 46, 376-379.	21.4	269
60	Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. Journal of Pathology, 2000, 190, 430-436.	4.5	268
61	The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib. Cancer Research, 2009, 69, 4415-4423.	0.9	263
62	Delta4, an endothelial specific Notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation, 2001, 69, 135-144.	1.9	262
63	Carbonic Anhydrase IX Expression, a Novel Surrogate Marker of Tumor Hypoxia, Is Associated With a Poor Prognosis in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2003, 21, 473-482.	1.6	262
64	Angiogenesis in Endocrine Tumors. Endocrine Reviews, 2003, 24, 600-632.	20.1	251
65	Enhancement of Tumor Growth and Vascular Density by Transfection of Vascular Endothelial Cell Growth Factor Into MCF-7 Human Breast Carcinoma Cells. Journal of the National Cancer Institute, 1995, 87, 213-219.	6.3	250
66	The Role of Carbonic Anhydrase 9 in Regulating Extracellular and Intracellular pH in Three-dimensional Tumor Cell Growths. Journal of Biological Chemistry, 2009, 284, 20299-20310.	3.4	249
67	Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene, 2000, 19, 6297-6305.	5.9	245
68	Isolation of cDNA clones encoding the β isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Research, 1992, 20, 5587-5592.	14.5	243
69	A Core Human Primary Tumor Angiogenesis Signature Identifies the Endothelial Orphan Receptor ELTD1 as a Key Regulator of Angiogenesis. Cancer Cell, 2013, 24, 229-241.	16.8	238
70	Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clinical Cancer Research, 2002, 8, 2595-604.	7.0	237
71	Hypoxia Inducible Carbonic Anhydrase IX, Marker of Tumour: Hypoxia, Survival Pathway and Therapy Target. Cell Cycle, 2004, 3, 159-162.	2.6	234
72	Vessel coâ€option in primary human tumors and metastases: an obstacle to effective antiâ€angiogenic treatment?. Cancer Medicine, 2013, 2, 427-436.	2.8	231

#	Article	IF	CITATIONS
73	Aberrant succination of proteins in fumarate hydrataseâ€deficient mice and HLRCC patients is a robust biomarker of mutation status. Journal of Pathology, 2011, 225, 4-11.	4.5	225
74	Hypoxia-Inducible Factor-1α Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer. Clinical Cancer Research, 2006, 12, 4562-4568.	7.0	223
75	Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncology, The, 2001, 2, 278-289.	10.7	222
76	Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Research, 2002, 62, 2493-7.	0.9	222
77	Amino Acid Sensing by mTORC1: Intracellular Transporters Mark the Spot. Cell Metabolism, 2016, 23, 580-589.	16.2	221
78	Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification. Clinical Cancer Research, 2004, 10, 7965-7971.	7.0	215
79	hsaâ€miRâ€210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer, 2010, 116, 2148-2158.	4.1	215
80	Carbonic Anhydrase IX Promotes Tumor Growth and Necrosis <i>In Vivo</i> and Inhibition Enhances Anti-VEGF Therapy. Clinical Cancer Research, 2012, 18, 3100-3111.	7.0	215
81	A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer. Clinical Cancer Research, 2013, 19, 4879-4888.	7.0	214
82	Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer. PLoS ONE, 2011, 6, e20980.	2.5	214
83	Expression of the Hypoxia-Inducible and Tumor-Associated Carbonic Anhydrases in Ductal Carcinoma in Situ of the Breast. American Journal of Pathology, 2001, 158, 1011-1019.	3.8	212
84	DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i> . Cancer Research, 2011, 71, 6073-6083.	0.9	212
85	Housekeeping proteins: A preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics, 2005, 5, 566-571.	2.2	211
86	Association of hypoxiaâ€inducible factors 1α and 2α with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer, 2002, 95, 1055-1063.	4.1	207
87	Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Cancer & Metabolism, 2013, 1, 3.	5.0	207
88	A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress. Nucleic Acids Research, 1994, 22, 4884-4889.	14.5	205
89	GLUTâ€l and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding. International Journal of Cancer, 2003, 104, 85-91.	5.1	205
90	Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvascular Research, 2008, 75, 144-154.	2.5	202

#	Article	IF	CITATIONS
91	Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nature Communications, 2014, 5, 5203.	12.8	195
92	Mechanisms of Multidrug Resistance in Cancer Treatment. Acta OncolÃ <sup>3</sup> gica, 1992, 31, 205-213.	1.8	189
93	Comprehensive Proteomic Analysis of Breast Cancer Cell Membranes Reveals Unique Proteins with Potential Roles in Clinical Cancer. Journal of Biological Chemistry, 2003, 278, 6482-6489.	3.4	187
94	Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. Journal of Pathology, 2003, 200, 195-206.	4.5	186
95	Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. Cancer & Metabolism, 2016, 4, 6.	5.0	186
96	Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Research, 2002, 62, 2957-61.	0.9	186
97	Tumor-associated Carbonic Anhydrase 9 Spatially Coordinates Intracellular pH in Three-dimensional Multicellular Growths. Journal of Biological Chemistry, 2008, 283, 20473-20483.	3.4	185
98	Lactate Dehydrogenase 5 Expression in Operable Colorectal Cancer: Strong Association With Survival and Activated Vascular Endothelial Growth Factor Pathway—A Report of the Tumour Angiogenesis Research Group. Journal of Clinical Oncology, 2006, 24, 4301-4308.	1.6	183
99	Hypoxia response and microRNAs: no longer two separate worlds. Journal of Cellular and Molecular Medicine, 2008, 12, 1426-1431.	3.6	182
100	Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?. Breast Cancer Research and Treatment, 1998, 52, 305-319.	2.5	180
101	A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2004, 10, 6528-6534.	7.0	180
102	Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 7177-7182.	7.1	180
103	Pyruvate Dehydrogenase and Pyruvate Dehydrogenase Kinase Expression in Non Small Cell Lung Cancer and Tumor-Associated Stroma. Neoplasia, 2005, 7, 1-6.	5.3	179
104	Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients. Journal of Clinical Oncology, 2006, 24, 3623-3628.	1.6	178
105	Plateletâ€derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: An immunohistochemical study. Journal of Pathology, 1995, 176, 183-190.	4.5	175
106	HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer. Journal of Clinical Investigation, 2020, 130, 5074-5087.	8.2	175
107	Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Reviews in Molecular Medicine, 2009, 11, e26.	3.9	173
108	Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy. Journal of Molecular Medicine, 2016, 94, 137-154.	3.9	172

#	Article	IF	CITATIONS
109	p53, c-erbB-2 and the Epidermal Growth Factor Receptor in the Benign and Malignant Prostate. Journal of Urology, 1992, 147, 496-499.	0.4	168
110	A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1. Genes and Development, 2017, 31, 353-369.	5.9	168
111	Tumor angiogenesis in node-negative breast carcinomas ? relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Research and Treatment, 1994, 29, 109-116.	2.5	167
112	Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2009, 24, 1-39.	5.2	167
113	The Histone Demethylase JMJD2B Is Regulated by Estrogen Receptor α and Hypoxia, and Is a Key Mediator of Estrogen Induced Growth. Cancer Research, 2010, 70, 6456-6466.	0.9	167
114	New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treatment Reviews, 2013, 39, 171-179.	7.7	167
115	Microvessel count predicts metastatic disease and survival in nonâ€small cell lung cancer. Journal of Pathology, 1995, 177, 57-63.	4.5	166
116	Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle, 2009, 8, 3838-3847.	2.6	166
117	Effects of Acute versus Chronic Hypoxia on DNA Damage Responses and Genomic Instability. Cancer Research, 2010, 70, 925-935.	0.9	166
118	Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis. Arthritis Research, 2003, 5, R193.	2.0	164
119	Activation of Peroxisome Proliferator-Activated Receptor $\hat{I}$ Stimulates the Proliferation of Human Breast and Prostate Cancer Cell Lines. Cancer Research, 2004, 64, 3162-3170.	0.9	163
120	Anoxic induction of ATF-4 through HIF-1–independent pathways of protein stabilization in human cancer cells. Blood, 2004, 103, 1876-1882.	1.4	162
121	Angiogenesis in Pituitary Adenomas and the Normal Pituitary Gland. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1159-1162.	3.6	161
122	Transcriptional Profiling of Human Cord Blood CD133+ and Cultured Bone Marrow Mesenchymal Stem Cells in Response to Hypoxia. Stem Cells, 2007, 25, 1003-1012.	3.2	161
123	Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer. Clinical Cancer Research, 2012, 18, 3428-3439.	7.0	158
124	The Notch ligand Jagged1 as a target for anti-tumor therapy. Frontiers in Oncology, 2014, 4, 254.	2.8	157
125	Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiotherapy and Oncology, 2011, 99, 424-431.	0.6	156
126	Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Research, 2002, 62, 1326-9.	0.9	156

#	Article	IF	CITATIONS
127	Hypoxia-inducible factor-1? in non small cell lung cancer: Relation to growth factor, protease and apoptosis pathways. International Journal of Cancer, 2004, 111, 43-50.	5.1	153
128	The Role of Copper in Tumour Angiogenesis. Journal of Mammary Gland Biology and Neoplasia, 2005, 10, 299-310.	2.7	153
129	Hypoxia-inducible factors 1?? and 2?? are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Research, 2003, 13, 493-501.	1.2	151
130	Mechanisms of resistance to antiangiogenesis therapy. European Journal of Cancer, 2010, 46, 1323-1332.	2.8	151
131	Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell–mediated immunotherapy. Journal of Clinical Investigation, 2004, 114, 1800-1811.	8.2	150
132	Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis. Journal of Cancer Research and Clinical Oncology, 2005, 131, 741-750.	2.5	147
133	Breast tumour angiogenesis. Breast Cancer Research, 2007, 9, 216.	5.0	146
134	Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Research, 2011, 13, R47.	5.0	146
135	Extensive regulation of the non oding transcriptome by hypoxia: role of <scp>HIF</scp> in releasing paused <scp>RNA</scp> pol2. EMBO Reports, 2014, 15, 70-76.	4.5	146
136	PROGNOSTIC VALUE OF ANGIOGENESIS IN OPERABLE NON-SMALL CELL LUNG CANCER. Journal of Pathology, 1996, 179, 80-88.	4.5	144
137	The Androgen Receptor Is Significantly Associated with Vascular Endothelial Growth Factor and Hypoxia Sensing via Hypoxia-Inducible Factors HIF-1a, HIF-2a, and the Prolyl Hydroxylases in Human Prostate Cancer. Clinical Cancer Research, 2005, 11, 7658-7663.	7.0	144
138	The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients. Breast Cancer Research and Treatment, 1994, 29, 41-49.	2.5	143
139	Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. Journal of Cellular and Molecular Medicine, 2010, 14, 18-29.	3.6	143
140	Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu. The Journal of Steroid Biochemistry, 1989, 34, 123-131.	1.1	141
141	Novel growth regulatory factors and tumour angiogenesis. European Journal of Cancer & Clinical Oncology, 1991, 27, 781-785.	0.7	141
142	BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors. Nature Communications, 2019, 10, 3143.	12.8	141
143	Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure. Journal of Steroid Biochemistry and Molecular Biology, 1990, 37, 811-814.	2.5	140
144	Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer. Clinical Cancer Research, 2015, 21, 955-961.	7.0	140

#	Article	IF	CITATIONS
145	Metabolic and hypoxic adaptation to antiâ€angiogenic therapy: a target for induced essentiality. EMBO Molecular Medicine, 2015, 7, 368-379.	6.9	136
146	Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia. Molecular Cancer, 2014, 13, 28.	19.2	135
147	Autophagosome Proteins LC3A, LC3B and LC3C Have Distinct Subcellular Distribution Kinetics and Expression in Cancer Cell Lines. PLoS ONE, 2015, 10, e0137675.	2.5	135
148	MicroRNA-10b and breast cancer metastasis. Nature, 2008, 455, E8-E9.	27.8	134
149	Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients. Clinical Cancer Research, 2009, 15, 1046-1051.	7.0	133
150	Histological quantitation of tumour angiogenesis. Apmis, 2004, 112, 413-430.	2.0	132
151	Vascular Patterns in Glioblastoma Influence Clinical Outcome and Associate with Variable Expression of Angiogenic Proteins: Evidence for Distinct Angiogenic Subtypes. Brain Pathology, 2003, 13, 133-143.	4.1	132
152	A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 2695-2703.	7.0	132
153	BNIP3 Expression Is Linked with Hypoxia-Regulated Protein Expression and with Poor Prognosis in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 5566-5571.	7.0	129
154	A Shift in the Phenotype of Melan-A-Specific CTL Identifies Melanoma Patients with an Active Tumor-Specific Immune Response. Journal of Immunology, 2000, 165, 6644-6652.	0.8	128
155	Hypoxia-induced genetic instability—a calculated mechanism underlying tumor progression. Journal of Molecular Medicine, 2007, 85, 139-148.	3.9	128
156	Transcriptional up-regulation of ULK1 by ATF4 contributes to cancer cell survival. Biochemical Journal, 2013, 449, 389-400.	3.7	128
157	Up-Regulation of Endothelial Delta-like 4 Expression Correlates with Vessel Maturation in Bladder Cancer. Clinical Cancer Research, 2006, 12, 4836-4844.	7.0	127
158	Mutant p53—the commonest genetic abnormality in human cancer?. Journal of Pathology, 1990, 162, 5-6.	4.5	125
159	Novel Mechanism of Action for Hydralazine. Circulation Research, 2004, 95, 162-169.	4.5	125
160	A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data. Genome Biology, 2010, 11, R92.	8.8	125
161	Hypoxia-Inducible Factor 1α Expression as an Intrinsic Marker of Hypoxia. Clinical Cancer Research, 2004, 10, 8405-8412.	7.0	123
162	Antiangiogenesis for cancer therapy. Lancet, The, 1997, 349, S13-S15.	13.7	122

#	Article	IF	CITATIONS
163	Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiotherapy and Oncology, 2005, 75, 89-98.	0.6	122
164	TUMOUR ANGIOGENESIS. , 1996, 179, 232-237.		120
165	The Presence of a Fibrotic Focus in Invasive Breast Carcinoma Correlates with the Expression of Carbonic Anhydrase IX and is a Marker of Hypoxia and Poor Prognosis. Breast Cancer Research and Treatment, 2003, 81, 137-147.	2.5	120
166	The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target. , 1998, 17, 187-194.		119
167	Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy. Clinical Cancer Research, 2011, 17, 4892-4900.	7.0	119
168	Bladder Cancer — Field versus Clonal Origin. New England Journal of Medicine, 1992, 326, 759-761.	27.0	118
169	URINARY VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS CORRELATION WITH BLADDER CANCER RECURRENCE RATES. Journal of Urology, 1999, 161, 799-804.	0.4	118
170	Association of Tumor Angiogenesis With Bone Marrow Micrometastases in Breast Cancer Patients. Journal of the National Cancer Institute, 1997, 89, 1044-1049.	6.3	116
171	Phosphorylated ERα, HIF-1α, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer. Journal of Clinical Oncology, 2009, 27, 227-234.	1.6	116
172	HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer. PLoS Biology, 2010, 8, e1000563.	5.6	116
173	Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Frontiers in Bioscience - Landmark, 2009, Volume, 3094.	3.0	115
174	Targeting the ATF4 pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 2012, 16, 1189-1202.	3.4	115
175	The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Research, 2002, 62, 5912-9.	0.9	115
176	High Serum YKL-40 Levels in Patients with Primary Breast Cancer is Related to Short Recurrence Free Survival. Breast Cancer Research and Treatment, 2003, 80, 15-21.	2.5	113
177	Non-angiogenic tumours and their influence on cancer biology. Nature Reviews Cancer, 2018, 18, 323-336.	28.4	113
178	MDM2 and MDMX bind and stabilize the p53-related protein p73. Current Biology, 1999, 9, 829-832.	3.9	111
179	Role of hypoxia-inducible factor-1α as a cancer therapy target. Endocrine-Related Cancer, 2006, 13, S61-S75.	3.1	110
180	Estrogen receptor-α directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15172-15177.	7.1	110

#	Article	IF	CITATIONS
181	Pan-cancer characterisation of microRNA across cancer hallmarks reveals microRNA-mediated downregulation of tumour suppressors. Nature Communications, 2018, 9, 5228.	12.8	110
182	Notch signaling from tumor cells: A new mechanism of angiogenesis. Cancer Cell, 2005, 8, 1-3.	16.8	109
183	A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients. Clinical Cancer Research, 2017, 23, 4761-4768.	7.0	107
184	Expression of the cell death genes BNip3 and NIX in ductal carcinomain situ of the breast; correlation of BNip3 levels with necrosis and grade. Journal of Pathology, 2003, 201, 573-580.	4.5	105
185	miR-139-5p Modulates Radiotherapy Resistance in Breast Cancer by Repressing Multiple Gene Networks of DNA Repair and ROS Defense. Cancer Research, 2018, 78, 501-515.	0.9	105
186	Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome. International Journal of Radiation Oncology Biology Physics, 2001, 50, 27-36.	0.8	104
187	Hypoxia-inducible factors and hypoxic cell death in tumour physiology. Annals of Medicine, 2004, 36, 530-539.	3.8	104
188	Distinct Molecular Signature of Inflammatory Breast Cancer by cDNA Microarray Analysis. Breast Cancer Research and Treatment, 2005, 93, 237-246.	2.5	104
189	The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer. Cancer and Metastasis Reviews, 2007, 26, 553-66.	5.9	104
190	Expression of Vascular Notch Ligand Delta-Like 4 and Inflammatory Markers in Breast Cancer. American Journal of Pathology, 2010, 176, 2019-2028.	3.8	104
191	Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. Journal of Pathology, 2002, 197, 314-321.	4.5	103
192	Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1. Clinical Cancer Research, 2005, 11, 3402-3409.	7.0	103
193	Importance of Intracellular pH in Determining the Uptake and Efficacy of the Weakly Basic Chemotherapeutic Drug, Doxorubicin. PLoS ONE, 2012, 7, e35949.	2.5	103
194	6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance. Cancer Research, 2010, 70, 6268-6276.	0.9	102
195	Nuclear Factor-κB Signature of Inflammatory Breast Cancer by cDNA Microarray Validated by Quantitative Real-time Reverse Transcription-PCR, Immunohistochemistry, and Nuclear Factor-κB DNA-Binding. Clinical Cancer Research, 2006, 12, 3249-3256.	7.0	101
196	LC3A-Positive Light Microscopy Detected Patterns of Autophagy and Prognosis in Operable Breast Carcinomas. American Journal of Pathology, 2010, 176, 2477-2489.	3.8	101
197	Prospective Study of Quantitation of Plasma DNA Levels in the Diagnosis of Malignant versus Benign Prostate Disease. Clinical Cancer Research, 2005, 11, 1394-1399.	7.0	100
198	Overexpression of <i>POLQ</i> Confers a Poor Prognosis in Early Breast Cancer Patients. Oncotarget, 2010, 1, 175-184.	1.8	100

#	Article	IF	CITATIONS
199	Necrosis and Hypoxia in Invasive Breast Carcinoma. Breast Cancer Research and Treatment, 2003, 81, 61-69.	2.5	99
200	The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecologic Oncology, 2008, 110, 216-221.	1.4	98
201	Role of Hypoxiaâ€Inducible Factors in Epigenetic Regulation via Histone Demethylases. Annals of the New York Academy of Sciences, 2009, 1177, 185-197.	3.8	98
202	Differential Gene Expression Patterns in HER2/neu-Positive and -Negative Breast Cancer Cell Lines and Tissues. American Journal of Pathology, 2002, 161, 1171-1185.	3.8	97
203	Regulation of intracellular pH in cancer cell lines under normoxia and hypoxia. Journal of Cellular Physiology, 2013, 228, 743-752.	4.1	97
204	The tumour hypoxia induced non-coding transcriptome. Molecular Aspects of Medicine, 2016, 47-48, 35-53.	6.4	96
205	Interleukin-4 is a potent mitogen for capillary endothelium. Biochemical and Biophysical Research Communications, 1991, 174, 1287-1293.	2.1	95
206	NOVELANGIOGENICSIGNALINGPATHWAYS ANDVASCULARTARGETS. Annual Review of Pharmacology and Toxicology, 2004, 44, 219-238.	9.4	95
207	Bcl-2 and p53 expression in node-negative breast carcinoma: A study with long-term follow-up. Human Pathology, 1996, 27, 1149-1155.	2.0	94
208	Phase I Study of MetXia-P450 Gene Therapy and Oral Cyclophosphamide for Patients with Advanced Breast Cancer or Melanoma. Clinical Cancer Research, 2005, 11, 1512-1520.	7.0	93
209	Immunodominance of Poxviral-Specific CTL in a Human Trial of Recombinant-Modified Vaccinia Ankara. Journal of Immunology, 2005, 175, 8431-8437.	0.8	93
210	Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 689-721.	5.2	93
211	Carbonic anhydrase IX is a pH-stat that sets an acidic tumour extracellular pH in vivo. British Journal of Cancer, 2018, 119, 622-630.	6.4	93
212	Hypoxia and oxidative stress in breast cancer Hypoxia and tumourigenesis. Breast Cancer Research, 2001, 3, 318-22.	5.0	92
213	The relation between hypoxiaâ€inducible factor (HIF)â€1α and HIFâ€2α expression with anemia and outcome in surgically treated head and neck cancer. Cancer, 2006, 107, 757-766.	4.1	92
214	Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer. Cell Metabolism, 2018, 28, 679-688.e4.	16.2	92
215	Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. International Journal of Cancer, 2005, 113, 259-266.	5.1	89
216	Niacin induces PPARÎ <sup>3</sup> expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochemical Pharmacology, 2006, 71, 646-656.	4.4	89

#	Article	IF	CITATIONS
217	Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies. Angiogenesis, 2008, 11, 41-51.	7.2	89
218	Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer. Clinical Cancer Research, 2011, 17, 372-381.	7.0	89
219	Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel‣indau gene and hypoxia. Journal of Pathology, 2002, 198, 502-510.	4.5	88
220	Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis. Gynecologic Oncology, 2006, 103, 912-918.	1.4	88
221	Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Research, 2008, 10, R26.	5.0	88
222	The angiogenic pathway ?vascular endothelial growth factor/flk-1(KDR)-receptor? in rheumatoid arthritis and osteoarthritis. Journal of Pathology, 2001, 194, 101-108.	4.5	87
223	Epigenetic downregulation of human disabled homolog 2 switches TGF-Î <sup>2</sup> from a tumor suppressor to a tumor promoter. Journal of Clinical Investigation, 2010, 120, 2842-2857.	8.2	87
224	A novel human Wnt gene, WNT10B, maps to 12q13 and is expressed in human breast carcinomas. Oncogene, 1997, 14, 1249-1253.	5.9	86
225	Hypoxic activation of the unfolded protein response (UPR) induces expression of the metastasis-associated gene LAMP3. Radiotherapy and Oncology, 2009, 92, 450-459.	0.6	86
226	Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 12452-12461.	7.1	86
227	Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1beta (HIF-1beta): evidence of an anabolic role for the HIF-1 pathway. Cancer Research, 2002, 62, 688-95.	0.9	86
228	c-Myc Interacts with Hypoxia to Induce Angiogenesis In vivo by a Vascular Endothelial Growth Factor-Dependent Mechanism. Cancer Research, 2004, 64, 6563-6570.	0.9	85
229	Expression of the Forkhead Transcription Factor FOXP1 Is Associated with Estrogen Receptor α and Improved Survival in Primary Human Breast Carcinomas. Clinical Cancer Research, 2004, 10, 3521-3527.	7.0	85
230	Phase I Study of Copper-Binding Agent ATN-224 in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2008, 14, 7526-7534.	7.0	85
231	Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clinical Cancer Research, 2002, 8, 1132-41.	7.0	85
232	Normoxic Stabilization of Hypoxia-Inducible Factor-1α by Modulation of the Labile Iron Pool in Differentiating U937 Macrophages: Effect of Natural Resistance–Associated Macrophage Protein 1. Cancer Research, 2006, 66, 2600-2607.	0.9	84
233	Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis?. Trends in Molecular Medicine, 2007, 13, 389-395.	6.7	84
234	Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica, 2010, 95, 776-784.	3.5	84

#	Article	IF	CITATIONS
235	p53 Regulates the Minimal Promoter of the Human Topoisomerase IIÂ Gene. Nucleic Acids Research, 1996, 24, 4464-4470.	14.5	83
236	Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer. Oncogene, 2005, 24, 1212-1219.	5.9	83
237	BHLHB2 Controls <i>Bdnf</i> Promoter 4 Activity and Neuronal Excitability. Journal of Neuroscience, 2008, 28, 1118-1130.	3.6	83
238	Prognostic relevance of light chain 3 (LC3A) autophagy patterns in colorectal adenocarcinomas. Journal of Clinical Pathology, 2010, 63, 867-872.	2.0	83
239	A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis. Oncogene, 2002, 21, 282-290.	5.9	82
240	Lactate Dehydrogenase 5 Expression in Squamous Cell Head and Neck Cancer Relates to Prognosis following Radical or Postoperative Radiotherapy. Oncology, 2009, 77, 285-292.	1.9	82
241	Human CHCHD4 mitochondrial proteins regulate cellular oxygen consumption rate and metabolism and provide a critical role in hypoxia signaling and tumor progression. Journal of Clinical Investigation, 2012, 122, 600-611.	8.2	82
242	Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas. Breast Cancer Research and Treatment, 1995, 35, 293-297.	2.5	81
243	BNIP3 as a Progression Marker in Primary Human Breast Cancer; Opposing Functions in In situ Versus Invasive Cancer. Clinical Cancer Research, 2007, 13, 467-474.	7.0	81
244	Disrupting Hypoxia-Induced Bicarbonate Transport Acidifies Tumor Cells and Suppresses Tumor Growth. Cancer Research, 2016, 76, 3744-3755.	0.9	81
245	Insulin-like growth factors in human breast cancer. Breast Cancer Research and Treatment, 1998, 52, 175-184.	2.5	80
246	Combined role of tumor angiogenesis,bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. , 1999, 86, 1421-1430.		80
247	Autophagy and lysosomal related protein expression patterns in human glioblastoma. Cancer Biology and Therapy, 2014, 15, 1468-1478.	3.4	80
248	Glycogen metabolism in cancer. Biochemical Pharmacology, 2014, 92, 3-11.	4.4	80
249	Regulation of the Human Topoisomerase IIα Gene Promoter in Confluence-arrested Cells. Journal of Biological Chemistry, 1996, 271, 16741-16747.	3.4	80
250	Increased expression of transcription factor EB (TFEB) is associated with autophagy, migratory phenotype and poor prognosis in non-small cell lung cancer. Lung Cancer, 2015, 90, 98-105.	2.0	79
251	DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. Journal of Pathology, 2003, 200, 222-228.	4.5	78
252	Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents. Cancer Research, 2009, 69, 7524-7528.	0.9	78

#	Article	IF	CITATIONS
253	The angiogenic process as a therapeutic target in cancer. Biochemical Pharmacology, 2011, 81, 1183-1191.	4.4	78
254	Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Letters, 2012, 323, 77-87.	7.2	78
255	c-erbB-2 Related Aggressiveness in Breast Cancer Is Hypoxia Inducible Factor-1α Dependent. Clinical Cancer Research, 2004, 10, 7972-7977.	7.0	77
256	Notch3 signalling promotes tumour growth in colorectal cancer. Journal of Pathology, 2011, 224, 448-460.	4.5	77
257	Effects of HIF-1 and HIF2 on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts. Journal of Oncology, 2010, 2010, 1-14.	1.3	76
258	Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells <i>in vitro</i> . Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 360-369.	5.2	76
259	Fatty Acid-binding Protein 4, a Point of Convergence for Angiogenic and Metabolic Signaling Pathways in Endothelial Cells. Journal of Biological Chemistry, 2014, 289, 23168-23176.	3.4	75
260	Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocrine-Related Cancer, 2006, 13, 921-930.	3.1	74
261	Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics, 2009, 10, 424.	2.8	74
262	The angiogenic ?vascular endothelial growth factor/flk-1(KDR) receptor? pathway in patients with endometrial carcinoma. Cancer, 2001, 92, 2569-2577.	4.1	73
263	Gene expression and hypoxia in breast cancer. Genome Medicine, 2011, 3, 55.	8.2	73
264	P21-Activated Kinase 1 (PAK1) as a Therapeutic Target in BRAF Wild-Type Melanoma. Journal of the National Cancer Institute, 2013, 105, 606-607.	6.3	73
265	MEF2 transcription factors are key regulators of sprouting angiogenesis. Genes and Development, 2016, 30, 2297-2309.	5.9	73
266	Resistance to Diverse Drugs and Ultraviolet Light Conferred by Overexpression of a Novel Human 26 S Proteasome Subunit. Journal of Biological Chemistry, 1997, 272, 30470-30475.	3.4	72
267	Spectral Clustering of Microarray Data Elucidates the Roles of Microenvironment Remodeling and Immune Responses in Survival of Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology, 2010, 28, 2881-2888.	1.6	72
268	Hypoxia induces a lipogenic cancer cell phenotype via HIF1α-dependent and -independent pathways. Oncotarget, 2015, 6, 1920-1941.	1.8	72
269	Angiogenesis as a biomarker and target in cancer chemoprevention. Lancet Oncology, The, 2001, 2, 726-732.	10.7	69
270	Antiangiogenic Therapy for von Hippel-Lindau Disease. JAMA - Journal of the American Medical Association, 2004, 291, 943-944.	7.4	69

#	Article	IF	CITATIONS
271	HIF-2α expression in human fetal paraganglia and neuroblastoma: relation to sympathetic differentiation, glucose deficiency, and hypoxia. Experimental Cell Research, 2005, 303, 447-456.	2.6	69
272	Notch Signaling in Breast Cancer and Tumor Angiogenesis: Cross-Talk and Therapeutic Potentials. Journal of Mammary Gland Biology and Neoplasia, 2006, 11, 41-52.	2.7	68
273	Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncology, The, 2007, 8, 488-499.	10.7	68
274	Targeting tumour hypoxia in breast cancer. European Journal of Cancer, 2008, 44, 2766-2773.	2.8	68
275	Drug inhibition of angiogenesis. Current Opinion in Pharmacology, 2002, 2, 403-414.	3.5	67
276	Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia. Genome Biology, 2016, 17, 140.	8.8	67
277	Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. European Journal of Cancer, 1992, 28, 805-810.	2.8	66
278	Validation of anti-vascular endothelial growth factor (anti-VEGF) antibodies for immunohistochemical localization of VEGF in tissue sections: expression of VEGF in the human endometrium. , 1998, 185, 402-408.		66
279	Cid1, a Fission Yeast Protein Required for S-M Checkpoint Control when DNA Polymerase δ or É> Is Inactivated. Molecular and Cellular Biology, 2000, 20, 3234-3244.	2.3	66
280	Effects of Transferrin Receptor Blockade on Cancer Cell Proliferation and Hypoxia-Inducible Factor Function and Their Differential Regulation by Ascorbate. Cancer Research, 2006, 66, 2749-2756.	0.9	66
281	ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget, 2014, 5, 6633-6646.	1.8	66
282	Expression of VEGF in routinely fixed material using a new monoclonal. , 1998, 186, 313-318.		65
283	HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells. PLoS ONE, 2008, 3, e2881.	2.5	65
284	Galectin-3 acts as an angiogenic switch to induce tumor angiogenesis via Jagged-1/Notch activation. Oncotarget, 2017, 8, 49484-49501.	1.8	65
285	Mechanisms and therapeutic implications of angiogenesis. Current Opinion in Oncology, 1996, 8, 60-65.	2.4	64
286	Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. , 1997, 15, 15-28.		64
287	Gorham-Stout Syndrome: A Monocyte-Mediated Cytokine Propelled Disease. Journal of Bone and Mineral Research, 2005, 21, 207-218.	2.8	64
288	Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. Journal of Molecular Medicine, 2013, 91, 749-758.	3.9	64

#	Article	IF	CITATIONS
289	Scarring, stem cells, scaffolds and skin repair. Journal of Tissue Engineering and Regenerative Medicine, 2015, 9, 649-668.	2.7	64
290	Clutamine deprivation alters the origin and function of cancer cell exosomes. EMBO Journal, 2020, 39, e103009.	7.8	64
291	Macrophages and the hypoxic tumour microenvironment. Frontiers in Bioscience - Landmark, 2007, 12, 4298.	3.0	63
292	The Role of Histone Demethylase KDM4B in Myc Signaling in Neuroblastoma. Journal of the National Cancer Institute, 2015, 107, djv080.	6.3	63
293	Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer. British Journal of Cancer, 2021, 124, 494-505.	6.4	62
294	Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer, 1999, 85, 1996-2000.	4.1	62
295	Cancer-associated, hypoxia-inducible carbonic anhydrase IX facilitates CO2diffusion. BJU International, 2008, 101, 22-24.	2.5	61
296	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). Journal of the National Cancer Institute Monographs, 2011–2011–147-151	2.1	61
297	Loss of HLA class-I alleles, heavy chains and β2-microglobulin in colorectal cancer. International Journal of Cancer, 1992, 51, 379-385.	5.1	60
298	CITED4 Inhibits Hypoxia-Activated Transcription in Cancer Cells, and Its Cytoplasmic Location in Breast Cancer Is Associated with Elevated Expression of Tumor Cell Hypoxia-Inducible Factor 1α. Cancer Research, 2004, 64, 6075-6081.	0.9	60
299	Hypoxia-regulated differentiation: let's step it up a Notch. Trends in Molecular Medicine, 2006, 12, 141-143.	6.7	60
300	Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septinâ€2 in renal cell carcinoma. Proteomics, 2006, 6, 3880-3893.	2.2	60
301	Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding. Molecular Cancer Therapeutics, 2006, 5, 2193-2202.	4.1	60
302	Non-linear survival analysis using neural networks. Statistics in Medicine, 2004, 23, 825-842.	1.6	59
303	Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget, 2014, 5, 5934-5949.	1.8	59
304	TRAP1 Regulates Proliferation, Mitochondrial Function, and Has Prognostic Significance in NSCLC. Molecular Cancer Research, 2014, 12, 660-669.	3.4	59
305	Endothelial Cell-Specific Expression of Tumor Necrosis Factor- <i>α</i> from the KDR or E-Selectin Promoters Following Retroviral Delivery. Human Gene Therapy, 1997, 8, 2239-2247.	2.7	58
306	Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet, The, 1999, 353, 1494-1495.	13.7	58

#	Article	IF	CITATIONS
307	â€~Invading edge vs. inner' (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. Journal of Pathology, 2000, 192, 140-149.	4.5	57
308	The hypoxia-regulated transcription factor DEC1(Stra13, SHARP-2) and its expression in human tissues and tumours. Journal of Pathology, 2004, 203, 808-813.	4.5	57
309	Prognostic Value of an Activation State Marker for Epidermal Growth Factor Receptor in Tissue Microarrays of Head and Neck Cancer. Cancer Research, 2006, 66, 2834-2843.	0.9	57
310	Delta-Like Ligand 4–Notch Blockade and Tumor Radiation Response. Journal of the National Cancer Institute, 2011, 103, 1778-1798.	6.3	57
311	Telling changes of base. Nature, 1991, 350, 377-378.	27.8	55
312	Regulation of Wnt5a mRNA Expression in Human Mammary Epithelial Cells by Cell Shape, Confluence, and Hepatocyte Growth Factor. Journal of Biological Chemistry, 1995, 270, 12851-12856.	3.4	55
313	VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. Journal of Pathology, 2001, 193, 325-332.	4.5	55
314	Notch regulation of tumor angiogenesis. Future Oncology, 2011, 7, 569-588.	2.4	55
315	Potential role ofbcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer. , 1997, 74, 565-570.		54
316	Role of the hypoxia sensing system, acidity and reproductive hormones in the variability of vascular endothelial growth factor induction in human breast carcinoma cell lines. , 1998, 75, 706-712.		54
317	von Hippelâ€Lindau Syndrome: Target for Antiâ€Vascular Endothelial Growth Factor (VEGF) Receptor Therapy. Oncologist, 2000, 5, 32-36.	3.7	54
318	Regulation of CXCR4 by the Notch Ligand Delta-like 4 in Endothelial Cells. Cancer Research, 2008, 68, 1889-1895.	0.9	54
319	Endothelial α3β1-Integrin Represses Pathological Angiogenesis and Sustains Endothelial-VEGF. American Journal of Pathology, 2010, 177, 1534-1548.	3.8	54
320	CD31 angiogenesis and combined expression of HIF-11± and HIF-21± are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIF1± transcriptional products are not: implications for antiangiogenic trials and HIF1± biomarker studies in primary CC-RCC. Carcinogenesis, 2012, 33, 1717-1725.	2.8	54
321	Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. Radiotherapy and Oncology, 2013, 108, 40-47.	0.6	54
322	The pH low insertion peptide pHLIP Variant 3 as a novel marker of acidic malignant lesions. Proceedings of the United States of America, 2015, 112, 9710-9715.	7.1	54
323	EARLY EXPRESSION OF bcl-2 PROTEIN IN THE ADENOMA-CARCINOMA SEQUENCE OF COLORECTAL NEOPLASIA. , 1996, 179, 10-14.		53
324	Endogenous markers of hypoxia/anaerobic metabolism and anemia in primary colorectal cancer. Cancer Science, 2006, 97, 582-588.	3.9	53

#	Article	IF	CITATIONS
325	Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunology, Immunotherapy, 2010, 59, 863-873.	4.2	53
326	Human endothelial stem/progenitor cells, angiogenic factors and vascular repair. Journal of the Royal Society Interface, 2010, 7, S731-51.	3.4	53
327	A small molecule targeting ALK1 prevents Notch cooperativity and inhibits functional angiogenesis. Angiogenesis, 2015, 18, 209-217.	7.2	53
328	Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus. Journal of Pathology, 2004, 202, 313-320.	4.5	52
329	An Investigation Into the Prognostic Significance of Necrosis and Hypoxia in High Grade and Invasive Bladder Cancer. Journal of Urology, 2007, 178, 677-682.	0.4	52
330	Down-Regulation of Phosphatidylinositol 3′-Kinase/AKT/Molecular Target of Rapamycin Metabolic Pathway by Primary Letrozole-Based Therapy in Human Breast Cancer. Clinical Cancer Research, 2008, 14, 2673-2680.	7.0	52
331	Phase I/II Trial of Bevacizumab and Radiotherapy for Locally Advanced Inoperable Colorectal Cancer: Vasculature-Independent Radiosensitizing Effect of Bevacizumab. Clinical Cancer Research, 2009, 15, 7069-7076.	7.0	52
332	Current approaches to targeting cancer using antiangiogenesis therapies. Cancer Treatment Reviews, 1994, 20, 393-412.	7.7	51
333	The epidermal growth factor receptor in breast cancer. Journal of Mammary Gland Biology and Neoplasia, 1997, 2, 131-141.	2.7	51
334	Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1α expression. Modern Pathology, 2006, 19, 9-16.	5.5	51
335	Macrophage Infiltration and Angiogenesis in Human Malignancy. Novartis Foundation Symposium, 2008, , 189-204.	1.1	51
336	Regulation of the tumour suppressor PDCD4 by miR-499 and miR-21 in oropharyngeal cancers. BMC Cancer, 2016, 16, 86.	2.6	51
337	The Role of Oxygen in Avascular Tumor Growth. PLoS ONE, 2016, 11, e0153692.	2.5	51
338	Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. International Journal of Oncology, 2005, 27, 401-7.	3.3	51
339	A study of adhesion molecules as markers of progression in malignant melanoma. Journal of Pathology, 1992, 167, 187-191.	4.5	50
340	Breast cancer angiogenesis — new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting. Breast Cancer Research and Treatment, 1996, 38, 97-108.	2.5	50
341	Platelet-derived endothelial cell growth factor (Thymidine Phosphorylase) expression in lung cancer. , 1997, 181, 196-199.		50
342	Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas. Journal of Pathology, 2002, 196, 416-422.	4.5	50

#	Article	IF	CITATIONS
343	Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. Cancer Letters, 2007, 253, 74-88.	7.2	50
344	Methods: Using Three-Dimensional Culture (Spheroids) as an In Vitro Model of Tumour Hypoxia. Advances in Experimental Medicine and Biology, 2016, 899, 167-196.	1.6	49
345	bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer. Clinical and Experimental Metastasis, 1999, 17, 545-554.	3.3	48
346	Mechanisms of Disease: angiogenesis in urologic malignancies. Nature Reviews Urology, 2006, 3, 157-169.	1.4	48
347	Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptorÎ <sup>2</sup> in primary invasive breast carcinomas. Breast Cancer Research and Treatment, 2008, 111, 453-459.	2.5	48
348	p21-activated kinase 1: PAK'ed with potential. Oncotarget, 2011, 2, 491-496.	1.8	48
349	The Unfolded Protein Response and Integrated Stress Response to Anoxia: Fig. 1 Clinical Cancer Research, 2007, 13, 2537-2540.	7.0	47
350	Nuclear localization of human AP endonuclease 1 (HAP1/Ref-1) associates with prognosis in early operable non-small cell lung cancer (NSCLC). , 1999, 189, 351-357.		46
351	Angiogenesis in bladder cancer—prognostic marker and target for future therapy. Surgical Oncology, 2002, 11, 85-100.	1.6	46
352	The Role of Hypoxia-Inducible Factor-1 in Three-dimensional Tumor Growth, Apoptosis, and Regulation by the Insulin-Signaling Pathway. Cancer Research, 2005, 65, 4147-4152.	0.9	46
353	Novel Thioredoxin Inhibitors Paradoxically Increase Hypoxia-Inducible Factor-α Expression but Decrease Functional Transcriptional Activity, DNA Binding, and Degradation. Clinical Cancer Research, 2006, 12, 5384-5394.	7.0	46
354	Tumor necrosis factor receptor-associated protein 1(TRAP1) regulates genes involved in cell cycle and metastases. Cancer Letters, 2010, 296, 194-205.	7.2	46
355	ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Research, 2012, 14, R46.	5.0	46
356	Hypoxia Induces Transcriptional and Translational Downregulation of the Type I IFN Pathway in Multiple Cancer Cell Types. Cancer Research, 2020, 80, 5245-5256.	0.9	46
357	Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. Journal of Pathology, 2001, 195, 236-243.	4.5	45
358	The HIF Pathway: Implications for Patterns of Gene Expression in Cancer. Novartis Foundation Symposium, 2001, 240, 212-231.	1.1	44
359	Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives. Biochemical Pharmacology, 1994, 48, 277-285.	4.4	43
360	Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival. Journal of Pathology, 2005, 205, 585-591.	4.5	43

#	Article	IF	CITATIONS
361	The role of topoisomerase IlÎ $\pm$ and Î $^2$ in drug resistance. Cancer Treatment Reviews, 1993, 19, 181-194.	7.7	42
362	Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX. European Journal of Pharmacology, 2011, 657, 173-183.	3.5	42
363	Assessing Early Therapeutic Response to Bevacizumab in Primary Breast Cancer Using Magnetic Resonance Imaging and Gene Expression Profiles. Journal of the National Cancer Institute Monographs, 2011, 2011, 71-74.	2.1	42
364	Expression of vascular Notch ligands Deltaâ€like 4 and Jaggedâ€1 in glioblastoma. Histopathology, 2012, 60, 740-747.	2.9	42
365	The glycerol backbone of phospholipids derives from noncarbohydrate precursors in starved lung cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 6225-6230.	7.1	42
366	Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer. European Journal of Cancer & Clinical Oncology, 1988, 24, 733-736.	0.7	41
367	Reduced topoisomerase II and elevated α class glutathione S-transferase expression in a multidrug resistant CHO cell line highly cross-resistant to mitomycin C. Biochemical Pharmacology, 1992, 43, 685-693.	4.4	41
368	Relation of Erythropoietin and Erythropoietin Receptor Expression to Hypoxia and Anemia in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2005, 11, 7614-7620.	7.0	41
369	Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer. Breast Cancer Research, 2007, 9, R89.	5.0	41
370	Single-cell heterogeneity in ductal carcinoma in situ of breast. Modern Pathology, 2018, 31, 406-417.	5.5	41
371	Expression of theforkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the Androgen receptor in prostate cancer but is not directly regulated by Androgens or hypoxia. Prostate, 2007, 67, 1091-1098.	2.3	40
372	Carbonic Anhydrase Activity Monitored <i>In Vivo</i> by Hyperpolarized 13C-Magnetic Resonance Spectroscopy Demonstrates Its Importance for pH Regulation in Tumors. Cancer Research, 2015, 75, 4109-4118.	0.9	40
373	Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 2459-2469.	7.0	40
374	Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2004, 59, 67-71.	0.8	39
375	Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients. International Journal of Cancer, 2006, 119, 2539-2545.	5.1	39
376	Intracellular Carbonic Anhydrase Activity Sensitizes Cancer Cell pH Signaling to Dynamic Changes in CO2 Partial Pressure. Journal of Biological Chemistry, 2014, 289, 25418-25430.	3.4	39
377	Hypoxia and Metabolism in Cancer. Advances in Experimental Medicine and Biology, 2014, 772, 1-39.	1.6	39
378	Carbonic anhydrase IX induction defines a heterogeneous cancer cell response to hypoxia and mediates stem cell-like properties and sensitivity to HDAC inhibition. Oncotarget, 2015, 6, 19413-19427.	1.8	39

#	Article	IF	CITATIONS
379	p53 Expression in Human Breast Cancer. Advances in Cancer Research, 1992, 59, 69-88.	5.0	38
380	The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions. Biochemical Pharmacology, 2000, 59, 993-996.	4.4	38
381	Phosphorylated KDR expression in endometrial cancer cells relates to HIF1α/VEGF pathway and unfavourable prognosis. Modern Pathology, 2006, 19, 701-707.	5.5	38
382	Expression of key hypoxia sensing prolylâ€hydroxylases PHD1, â€2 and â€3 in pancreaticobiliary cancer. Histopathology, 2010, 56, 908-920.	2.9	38
383	Angiogenesis in Pituitary Adenomas and the Normal Pituitary Gland. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1159-1162.	3.6	38
384	O-glycan sialylation alters galectin-3 subcellular localization and decreases chemotherapy sensitivity in gastric cancer. Oncotarget, 2016, 7, 83570-83587.	1.8	38
385	Exon Array Analysis of Head and Neck Cancers Identifies a Hypoxia Related Splice Variant of LAMA3 Associated with a Poor Prognosis. PLoS Computational Biology, 2009, 5, e1000571.	3.2	37
386	Expression of hypoxiaâ€associated proteins in sporadic medullary thyroid cancer is associated with desmoplastic stroma reaction and lymph node metastasis and may indicate somatic mutations in the <i>VHL</i> gene. Journal of Pathology, 2011, 225, 63-72.	4.5	37
387	Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma. European Journal of Cancer, 2013, 49, 156-165.	2.8	36
388	miR-193a-3p interaction with HMGB1 downregulates human endothelial cell proliferation and migration. Scientific Reports, 2017, 7, 44137.	3.3	36
389	Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis. Medical Oncology, 2019, 36, 76.	2.5	36
390	Proline-Hydroxylated Hypoxia-Inducible Factor 1α (HIF-1α) Upregulation in Human Tumours. PLoS ONE, 2014, 9, e88955.	2.5	36
391	The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16–213, doxorubicin and vincristine (VPAV) for small cell lung cancer. European Journal of Cancer & Clinical Oncology, 1988, 24, 123-129.	0.7	35
392	Inclusion of Vasculature-Related Variables in the Dukes Staging System of Colon Cancer. Clinical Cancer Research, 2005, 11, 8653-8660.	7.0	35
393	C2028T polymorphism in exon 12 and dinucleotide repeat polymorphism in intron 13 of the HIF-1α gene define HIF-1α protein expression in non-small cell lung cancer. Lung Cancer, 2006, 53, 257-262.	2.0	35
394	Copper chelator ATN-224 inhibits endothelial function by multiple mechanisms. Microvascular Research, 2009, 77, 314-326.	2.5	35
395	Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Research and Treatment, 2010, 124, 79-88.	2.5	35
396	Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth. Oncotarget, 2017, 8, 40115-40131.	1.8	35

#	Article	IF	CITATIONS
397	Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer. Cancer, 1994, 74, 1021-1025.	4.1	34
398	Are angiostatin and endostatin cures for cancer?. Lancet, The, 1998, 351, 1598-1599.	13.7	34
399	Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival. Acta Neuropathologica, 2005, 109, 211-216.	7.7	34
400	Phosphorylated KDR can be located in the nucleus of neoplastic cells. Cell Research, 2006, 16, 93-98.	12.0	34
401	The Role of Hypoxia Regulated microRNAs in Cancer. Current Topics in Microbiology and Immunology, 2010, 345, 47-70.	1.1	34
402	Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. International Journal of Oncology, 2005, 27, 401.	3.3	33
403	A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 2013, 72, 1343-1352.	2.3	33
404	In vitro downregulated hypoxia transcriptome is associated with poor prognosis in breast cancer. Molecular Cancer, 2017, 16, 105.	19.2	33
405	Angiogenesisvs. response after combined chemoradiotherapy of squamous cell head and neck cancer. , 1999, 80, 810-817.		32
406	Roles of Tetrahydrobiopterin in Promoting Tumor Angiogenesis. American Journal of Pathology, 2010, 177, 2671-2680.	3.8	32
407	A Novel Metal-Based Imaging Probe for Targeted Dual-Modality SPECT/MR Imaging of Angiogenesis. Frontiers in Chemistry, 2018, 6, 224.	3.6	32
408	Unveiling Cancer Metabolism through Spontaneous and Coherent Raman Spectroscopy and Stable Isotope Probing. Cancers, 2021, 13, 1718.	3.7	32
409	Detection of Mammaglobin mRNA in the Plasma of Breast Cancer Patients. Annals of the New York Academy of Sciences, 2001, 945, 192-194.	3.8	31
410	A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2009, 15, 4978-4985.	7.0	31
411	Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer. Clinical Cancer Research, 2011, 17, 3005-3012.	7.0	31
412	Development of Therapeutic Anti-JAGGED1 Antibodies for Cancer Therapy. Molecular Cancer Therapeutics, 2019, 18, 2030-2042.	4.1	31
413	A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma. European Journal of Cancer & Clinical Oncology, 1989, 25, 911-912.	0.7	30
414	Phosphorylated VEGFR2/KDR receptors are widely expressed in Bâ€cell nonâ€Hodgkin's lymphomas and correlate with hypoxia inducible factor activation. Hematological Oncology, 2008, 26, 219-224.	1.7	30

#	Article	IF	CITATIONS
415	Measuring Angiogenic Cytokines, Circulating Endothelial Cells, and Endothelial Progenitor Cells in Peripheral Blood and Cord Blood: VEGF and CXCL12 Correlate with the Number of Circulating Endothelial Progenitor Cells in Peripheral Blood. Tissue Engineering - Part C: Methods, 2008, 14, 59-67.	2.1	30
416	Vascular-Promoting Therapy Reduced Tumor Growth and Progression by Improving Chemotherapy Efficacy. Cancer Cell, 2015, 27, 7-9.	16.8	30
417	Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer. Oncotarget, 2015, 6, 5678-5694.	1.8	30
418	Non-Nuclear Localized Human NOSII Enhances the Bioactivation and Toxicity of Tirapazamine (SR4233) in Vitro. Molecular Pharmacology, 2003, 63, 1248-1255.	2.3	29
419	Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1α. Cancer Chemotherapy and Pharmacology, 2004, 53, 8-14.	2.3	29
420	The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-21± but not HIF-11±. Prostate, 2007, 67, 623-629.	2.3	29
421	ATF4 orchestrates a program of BH3-only protein expression in severe hypoxia. Molecular Biology Reports, 2012, 39, 10811-10822.	2.3	29
422	Hypoxia metabolism in ageing. Aging, 2015, 7, 465-466.	3.1	29
423	Hypoxia and Hormone-Mediated Pathways Converge at the Histone Demethylase KDM4B in Cancer. International Journal of Molecular Sciences, 2018, 19, 240.	4.1	29
424	The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemotherapy and Pharmacology, 2011, 68, 1485-1495.	2.3	28
425	Gene Expression Analysis in Human Breast Cancer Associated Blood Vessels. PLoS ONE, 2012, 7, e44294.	2.5	28
426	Molecular Basis for Jagged-1/Serrate Ligand Recognition by the Notch Receptor. Journal of Biological Chemistry, 2013, 288, 7305-7312.	3.4	28
427	Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. British Journal of Cancer, 2020, 122, 258-265.	6.4	28
428	Does improved control of tumour growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells?. European Journal of Cancer, 1994, 30, 201-206.	2.8	27
429	Expression of Wnt5a Is Downregulated by Extracellular Matrix and Mutated c-Ha-ras in the Human Mammary Epithelial Cell Line MCF-10A. Biochemical and Biophysical Research Communications, 1997, 239, 911-917.	2.1	27
430	Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer, 1999, 85, 1996-2000.	4.1	27
431	Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment. EBioMedicine, 2016, 10, 109-116.	6.1	27
432	Normal tissue radioprotection by amifostine via Warburg-type effects. Scientific Reports, 2016, 6, 30986.	3.3	27

#	Article	IF	CITATIONS
433	High-resolution imaging mass spectrometry combined with transcriptomic analysis identified a link between fatty acid composition of phosphatidylinositols and the immune checkpoint pathway at the primary tumour site of breast cancer. British Journal of Cancer, 2020, 122, 245-257.	6.4	27
434	Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect. Oncotarget, 2016, 7, 76613-76627.	1.8	27
435	Molecular Chemotherapy for Breast Cancer. Drugs and Aging, 1999, 14, 75-90.	2.7	26
436	Development of cancer metabolism as a therapeutic target: new pathways, patient studies, stratification and combination therapy. British Journal of Cancer, 2020, 122, 1-3.	6.4	26
437	Expression and functions of long non-coding RNA NEAT1 and isoforms in breast cancer. British Journal of Cancer, 2022, 126, 551-561.	6.4	26
438	Isolation and properties in culture of human adrenal capillary endothelial cells. Biochemical and Biophysical Research Communications, 1991, 174, 903-908.	2.1	25
439	An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease. Cancer Chemotherapy and Pharmacology, 1995, 37, 134-138.	2.3	25
440	A Novel Cyclic Adenosine Monophosphate Analog Induces Hypercalcemia via Production of 1,25-Dihydroxyvitamin D in Patients with Solid Tumors. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 4044-4048.	3.6	25
441	Angiogenesis in ductal breast carcinoma. Comparison of microvessel density between primary tumour and lymph node metastasis. Cancer Letters, 1999, 137, 145-150.	7.2	25
442	A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979). British Journal of Clinical Pharmacology, 2003, 56, 46-56.	2.4	25
443	A review of ELTD1, a pro-angiogenic adhesion GPCR. Biochemical Society Transactions, 2014, 42, 1658-1664.	3.4	25
444	Expression of xenobiotic-metabolizing enzymes by primary and secondary hepatic tumors in man. International Journal of Radiation Oncology Biology Physics, 1994, 29, 277-283.	0.8	24
445	The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR) Tj ETQq1 1 C	.784314 r 0.8	gBT/Overlo 24
446	Repair of cisplatin-DNA adducts by protein extracts from human ovarian carcinoma. International Journal of Cancer, 1994, 59, 388-393.	5.1	24
447	The Role of Cell-Free DNA Size Distribution in the Management of Prostate Cancer. Oncology Research, 2006, 16, 35-41.	1.5	24
448	The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-11̂± and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen. Breast Cancer Research, 2011, 13, R16.	5.0	24
449	Microvessel networks in pre-formed in artificial clinical grade dermal substitutes in vitro using cells from haematopoietic tissues. Burns, 2012, 38, 691-701.	1.9	24
450	Biological and Prognostic Significance of the Morphological Types and Vascular Patterns in Colorectal Liver Metastases (CRLM). Medicine (United States), 2016, 95, e2924.	1.0	24

#	Article	IF	CITATIONS
451	FOXP3 infiltrating lymphocyte density and PD-L1 expression in operable non-small cell lung carcinoma. Experimental Lung Research, 2019, 45, 76-83.	1.2	24
452	Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration. British Journal of Cancer, 2020, 122, 1205-1210.	6.4	24
453	Phase II study of doxorubicin plus ifosfamide/mesna in patients with advanced breast cancer. Cancer, 1990, 65, 2421-2425.	4.1	23
454	Enhancement of adriamycin® cytotoxicity in a multidrug resistant Chinese hamster ovary (CHO) subline, CHO-Adrr, by toremifene and its modulation by alpha1 acid glycoprotein. European Journal of Cancer & Clinical Oncology, 1990, 26, 432-436.	0.7	23
455	Thymidine phosphorylase expression in endometrial carcinomas. Clinical and Experimental Metastasis, 1999, 17, 445-450.	3.3	23
456	Adaptation to HIF-1 deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase activation in hepatomas. BMC Cancer, 2011, 11, 198.	2.6	23
457	RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition. PLoS ONE, 2018, 13, e0191890.	2.5	23
458	Guidelines for using sigQC for systematic evaluation of gene signatures. Nature Protocols, 2019, 14, 1377-1400.	12.0	23
459	Reciprocal interactions between tumour cell populations enhance growth and reduce radiation sensitivity in prostate cancer. Communications Biology, 2021, 4, 6.	4.4	23
460	Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer. Cancer, 1994, 74, 1021-1025.	4.1	23
461	Proline synthesis through PYCR1 is required to support cancer cell proliferation and survival in oxygen-limiting conditions. Cell Reports, 2022, 38, 110320.	6.4	23
462	What is the biological, prognostic, and therapeutic role of the EGF receptor in human breast cancer?. Breast Cancer Research and Treatment, 1994, 29, 1-2.	2.5	22
463	Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway. Cancer Letters, 2008, 262, 87-93.	7.2	22
464	The G-Protein–Coupled Receptor CLR Is Upregulated in an Autocrine Loop with Adrenomedullin in Clear Cell Renal Cell Carcinoma and Associated with Poor Prognosis. Clinical Cancer Research, 2013, 19, 5740-5748.	7.0	22
465	Imaging oligometastatic cancer before local treatment. Lancet Oncology, The, 2016, 17, e406-e414.	10.7	22
466	Adaptation to HIF1α Deletion in Hypoxic Cancer Cells by Upregulation of GLUT14 and Creatine Metabolism. Molecular Cancer Research, 2019, 17, 1531-1544.	3.4	22
467	An Immunohistochemical and Prognostic Evaluation of Cathepsin D Expression in 105 Bladder Carcinomas. Journal of Urology, 1995, 154, 237-241.	0.4	21
468	Isolation of a full-length human WNT7A gene implicated in limb development and cell transformation, and mapping to chromosome 3p25. Gene, 1997, 189, 25-29.	2.2	21

#	Article	IF	CITATIONS
469	Expression of BNIP3 correlates with hypoxiaâ€inducible factor (HIF)â€1α, HIFâ€2α and the androgen receptor in prostate cancer and is regulated directly by hypoxia but not androgens in cell lines. Prostate, 2008, 68, 336-343.	2.3	21
470	New pathways and mechanisms regulating and responding to Delta-like ligand 4–Notch signalling in tumour angiogenesis. Biochemical Society Transactions, 2011, 39, 1612-1618.	3.4	21
471	Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing. Journal of Physical Education and Sports Management, 2018, 4, a002279.	1.2	21
472	Machine learning to guide the use of adjuvant therapies for breast cancer. Nature Machine Intelligence, 2021, 3, 716-726.	16.0	21
473	Potential for protein kinase C inhibitors in cancer therapy. Cancer Treatment and Research, 1995, 78, 3-27.	0.5	21
474	ROLE OF THYMIDINE PHOSPHORYLASE IN AN IN VITRO MODEL OF HUMAN BLADDER CANCER INVASION. Journal of Urology, 2002, 167, 1482-1486.	0.4	20
475	The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy. Cancer Chemotherapy and Pharmacology, 2004, 53, 123-128.	2.3	20
476	The mevalonate precursor enzyme HMGCS1 is a novel marker and key mediator of cancer stem cell enrichment in luminal and basal models of breast cancer. PLoS ONE, 2020, 15, e0236187.	2.5	20
477	RHOQ is induced by DLL4 and regulates angiogenesis by determining the intracellular route of the Notch intracellular domain. Angiogenesis, 2020, 23, 493-513.	7.2	20
478	Angiogenesis in Breast Cancer Annals of the New York Academy of Sciences, 1993, 698, 71-84.	3.8	19
479	cDNA Cloning of a Humandishevelled DVL-3Gene, Mapping to 3q27, and Expression in Human Breast and Colon Carcinomas. Biochemical and Biophysical Research Communications, 1997, 239, 510-516.	2.1	19
480	Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen. Cancer Chemotherapy and Pharmacology, 2000, 45, 111-119.	2.3	19
481	Noninvasive Measurements of Capecitabine Metabolism in Bladder Tumors Overexpressing Thymidine Phosphorylase by Fluorine-19 Magnetic Resonance Spectroscopy. Clinical Cancer Research, 2004, 10, 3863-3870.	7.0	19
482	The Potential of New Tumor Endothelium-Specific Markers for the Development of Antivascular Therapy. Cancer Cell, 2007, 11, 478-481.	16.8	19
483	The Hematopoietic Chemokine CXCL12 Promotes Integration of Human Endothelial Colony Forming Cell–Derived Cells into Immature Vessel Networks. Stem Cells and Development, 2014, 23, 2730-2743.	2.1	19
484	Expression of bone morphogenetic protein 2 in breast cancer cells inhibits hypoxic cell death. International Journal of Oncology, 2005, 26, 1465-70.	3.3	19
485	Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target. Cancer and Metastasis Reviews, 1996, 15, 221-230.	5.9	18
486	Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins. Leukemia and Lymphoma, 2008, 49, 2181-2186.	1.3	18

#	Article	IF	CITATIONS
487	Synchronised phosphorylation of BNIP3, Bcl-2 and Bcl-xL in response to microtubule-active drugs is JNK-independent and requires a mitotic kinase. Biochemical Pharmacology, 2010, 79, 1562-1572.	4.4	18
488	Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncology, 2010, 6, 1099-1103.	2.4	18
489	MicroRNA-Related DNA Repair/Cell-Cycle Genes Independently Associated With Relapse After Radiation Therapy for Early Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1104-1114.	0.8	18
490	The prognostic and therapeutic implications of distinct patterns of argininosuccinate synthase 1 (ASS1) and arginase-2 (ARG2) expression by cancer cells and tumor stroma in non-small-cell lung cancer. Cancer & Metabolism, 2021, 9, 28.	5.0	18
491	Defective repair of DNA single- and double-strand breaks in the bleomycin- and X-ray-sensitive Chinese hamster ovary cell mutant, BLM-2. Mutation Research DNA Repair, 1989, 217, 93-100.	3.7	17
492	Modulation of dipyridamole action by α1acid glycoprotein. Biochemical Pharmacology, 1989, 38, 3281-3288.	4.4	17
493	Neo-angiogenesis in locally advanced squamous cell head and neck cancer correlates with thymidine phosphorylase expression and p53 nuclear oncoprotein accumulation. Clinical and Experimental Metastasis, 1998, 16, 665-672.	3.3	17
494	Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions. Expert Opinion on Therapeutic Targets, 2012, 16, 463-480.	3.4	17
495	The use of bioâ€metal concentrations correlated with clinical prognostic factors to assess human breast tissues. X-Ray Spectrometry, 2013, 42, 330-336.	1.4	17
496	Incomplete Dll4/Notch signaling inhibition promotes functional angiogenesis supporting the growth of skin papillomas. BMC Cancer, 2015, 15, 608.	2.6	17
497	3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism Modifiers. Molecular Cancer Therapeutics, 2019, 18, 376-388.	4.1	17
498	Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasion. British Journal of Cancer, 2020, 123, 137-147.	6.4	17
499	Paracrine effect of GTP cyclohydrolase and angiopoietin-1 interaction in stromal fibroblasts on tumor Tie2 activation and breast cancer growth. Oncotarget, 2016, 7, 9353-9367.	1.8	17
500	The onset of circulation triggers a metabolic switch required for endothelial to hematopoietic transition. Cell Reports, 2021, 37, 110103.	6.4	17
501	Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells. Biochemical Pharmacology, 1988, 37, 2113-2120.	4.4	16
502	Nuclear and membrane expression of the angiogenesis regulator deltaâ€like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology, 2009, 54, 598-606.	2.9	16
503	The heparan sulfate editing enzyme Sulf1 plays a novel role in zebrafish VegfA mediated arterial venous identity. Angiogenesis, 2014, 17, 77-91.	7.2	16
504	Landscape of transcriptomic interactions between breast cancer and its microenvironment. Nature Communications, 2019, 10, 3116.	12.8	16

#	Article	IF	CITATIONS
505	COVID-19 and cancer research. British Journal of Cancer, 2020, 123, 689-690.	6.4	16
506	Interferon- and STING-independent induction of type I interferon stimulated genes during fractionated irradiation. Journal of Experimental and Clinical Cancer Research, 2021, 40, 161.	8.6	16
507	Anti-angiogenic therapies in cancer clinical trials. Expert Opinion on Investigational Drugs, 1998, 7, 1629-1655.	4.1	15
508	Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix. Annals of Diagnostic Pathology, 2000, 4, 286-292.	1.3	15
509	Metabolic profiling of hypoxia-inducible factor- $1\hat{l}^2$ -deficient and wild type Hepa-1 cells: effects of hypoxia measured by 1H magnetic resonance spectroscopy. Metabolomics, 2006, 1, 293-303.	3.0	15
510	Acid-extrusion from Tissue: The Interplay Between Membrane Transporters and pH Buffers. Current Pharmaceutical Design, 2012, 18, 1331-1337.	1.9	15
511	Clinical imaging of tumor angiogenesis. Future Oncology, 2012, 8, 1443-1459.	2.4	15
512	An in vivo hypoxia metagene identifies the novel hypoxia inducible factor target gene SLCO1B3. European Journal of Cancer, 2013, 49, 1741-1751.	2.8	15
513	High DLL4 expression in tumour-associated vessels predicts for favorable radiotherapy outcome in locally advanced squamous cell head-neck cancer (HNSCC). Angiogenesis, 2013, 16, 343-351.	7.2	15
514	Why some tumours trigger neovascularisation and others don't: the story thus far. Chinese Journal of Cancer, 2016, 35, 18.	4.9	15
515	Targeting glycogen metabolism: a novel strategy to inhibit cancer cell growth?. Oncotarget, 2013, 4, 3-4.	1.8	15
516	Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer. European Journal of Cancer & Clinical Oncology, 1989, 25, 1105-1111.	0.7	14
517	Cathepsin D levels in primary breast cancers: Relationship with epidermal growth factor receptor, oestrogen receptor and axillary nodal status. European Journal of Cancer, 1993, 29, 426-428.	2.8	14
518	Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: relation with HIF2α and survival. Clinical and Experimental Metastasis, 2012, 29, 11-17.	3.3	14
519	Functional Parameters Derived from Magnetic Resonance Imaging Reflect Vascular Morphology in Preclinical Tumors and in Human Liver Metastases. Clinical Cancer Research, 2018, 24, 4694-4704.	7.0	14
520	ADGRL4/ELTD1 Silencing in Endothelial Cells Induces ACLY and SLC25A1 and Alters the Cellular Metabolic Profile. Metabolites, 2019, 9, 287.	2.9	14
521	The quantitation by radioimmunoassay of 2′-deoxyuridine 5′-triphosphate in extracts of thymidylate synthase-inhibited cells. Analytical Biochemistry, 1989, 177, 347-352.	2.4	13
522	Thymidine Phosphorylase Expression in Gallbladder Adenocarcinomas. International Journal of Surgical Pathology, 2002, 10, 181-188.	0.8	13

#	Article	IF	CITATIONS
523	Regulation of Hepatocyte Growth Factor Activator Inhibitor 2 by Hypoxia in Breast Cancer. Clinical Cancer Research, 2007, 13, 550-558.	7.0	13
524	Targeting Vascular Endothelial Growth Factor in Renal Cell Carcinoma. Tumor Biology, 2009, 30, 292-299.	1.8	13
525	Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients. Breast Cancer Research and Treatment, 2010, 123, 795-804.	2.5	13
526	Overexpression of LC3A autophagy protein in follicular and diffuse large B-cell lymphomas. Hematology/ Oncology and Stem Cell Therapy, 2013, 6, 20-25.	0.9	13
527	A New Hydroxy Metabolite of 2-Oxoglutarate Regulates Metabolism in Hypoxia. Cell Metabolism, 2015, 22, 198-200.	16.2	13
528	The Role of pH Regulation in Cancer Progression. Recent Results in Cancer Research, 2016, 207, 93-134.	1.8	13
529	SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapy. Investigational New Drugs, 2018, 36, 773-781.	2.6	13
530	The Landscape of the Heritable Cancer Genome. Cancer Research, 2021, 81, 2588-2599.	0.9	13
531	Hypoxia Regulates Endogenous Double-Stranded RNA Production via Reduced Mitochondrial DNA Transcription. Frontiers in Oncology, 2021, 11, 779739.	2.8	13
532	Clinical trials of anti-vascular agent group B Streptococcus toxin (CM101). Angiogenesis, 1997, 1, 36-37.	7.2	12
533	Preparation of the iodine-124 derivative of the Bolton-Hunter reagent ([124I]I-SHPP) and its use for labelling a VEGF antibody as a PET tracer. Journal of Labelled Compounds and Radiopharmaceuticals, 2002, 45, 1077-1090.	1.0	12
534	Differential assessment of angiogenic activity and of vascular survival ability (VSA) in breast cancer. Clinical and Experimental Metastasis, 2002, 19, 673-679.	3.3	12
535	High-dose i.v. granisetron for the prevention of chemotherapy-induced emesis: cardiac safety and tolerability. Anti-Cancer Drugs, 2003, 14, 739-744.	1.4	12
536	Expression of Hypoxia-related Tissue Factors Correlates with Diminished Survival of Adjuvantly Treated Patients with Chromosome 1p Aberrant Oligodendroglial Neoplasms and Therapeutic Implications. Clinical Cancer Research, 2004, 10, 6567-6571.	7.0	12
537	JMY protein, a regulator of P53 and cytoplasmic actin filaments, is expressed in normal and neoplastic tissues. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 715-722.	2.8	12
538	Informed Consent, Biobank Research, and Locality. Journal of Empirical Research on Human Research Ethics, 2014, 9, 48-55.	1.3	12
539	Seven In Absentia Homolog 2 (SIAH2) downregulation is associated with tamoxifen resistance in MCF-7 breast cancer cells. Journal of Surgical Research, 2014, 190, 203-209.	1.6	12
540	Labeling and preliminary in vivo assessment of niobium-labeled radioactive species: A proof-of-concept study. Nuclear Medicine and Biology, 2016, 43, 280-287.	0.6	12

#	Article	IF	CITATIONS
541	Targeting hypoxia regulated sodium driven bicarbonate transporters reduces triple negative breast cancer metastasis. Neoplasia, 2022, 25, 41-52.	5.3	12
542	More About: Tumor Angiogenesis as a Prognostic Assay for Invasive Ductal Breast Carcinoma. Journal of the National Cancer Institute, 2000, 92, 161-162.	6.3	11
543	8-Cl-adenosine is an active metabolite of 8-Cl-cAMP responsible for its in vitro antiproliferative effects on CHO mutants hypersensitive to cytostatic drugs. Cancer Chemotherapy and Pharmacology, 2001, 48, 451-458.	2.3	11
544	Angiogenesis - still a worthwhile target for breast cancer therapy?. Breast Cancer Research, 2010, 12, S19.	5.0	11
545	Targeting Carbonic Anhydrases with Fluorescent BODIPY‣abelled Sulfonamides. European Journal of Inorganic Chemistry, 2012, 2012, 2898-2907.	2.0	11
546	Disruption of hypoxia-inducible fatty acid binding protein 7 induces beige fat-like differentiation and thermogenesis in breast cancer cells. Cancer & Metabolism, 2020, 8, 13.	5.0	11
547	Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast. British Journal of Cancer, 2021, 124, 1150-1159.	6.4	11
548	c-erbB-2 and Episialin Challenge Host Immune Response by HLA Class I Expression in Human Non–Small-Cell Lung Cancer. Journal of Immunotherapy, 2000, 23, 104-114.	2.4	11
549	Modulation by verapamil of vincristine pharmacokinetics and sensitivity to metaphase arrest of the normal rat colon in organ culture. Biochemical Pharmacology, 1991, 41, 1217-1225.	4.4	10
550	Re: Tumor Angiogenesis as a Prognostic Assay for Invasive Ductal Breast Carcinoma. Journal of the National Cancer Institute, 1995, 87, 1798-1799.	6.3	10
551	Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[11C]-thymidine. Biochimica Et Biophysica Acta: Reviews on Cancer, 2004, 1705, 91-102.	7.4	10
552	Antiangiogenic Activity of a Domain Deletion Mutant of Tissue Plasminogen Activator Containing Kringle 2. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 736-741.	2.4	10
553	Role of gene signatures combined with pathology in classification of oropharynx head and neck cancer. Scientific Reports, 2020, 10, 10226.	3.3	10
554	Dissecting the heritable risk of breast cancer: From statistical methods to susceptibility genes. Seminars in Cancer Biology, 2021, 72, 175-184.	9.6	10
555	Prognostic Significance of Tumor Vascularity. , 1999, , 317-339.		10
556	Adenosine-diphosphoribosyltransferase inhibitors can protect against or potentiate the cytotoxicity of S-phase acting drugs. Biochemical Pharmacology, 1988, 37, 2155-2160.	4.4	9
557	Cisplatin with high-dose infusions of hydroxyurea to inhibit DNA repair. Cancer Chemotherapy and Pharmacology, 1989, 23, 252-254.	2.3	9
558	177Lu-labeled-VG76e monoclonal antibody in tumor angiogenesis: A comparative study using DOTA and DTPA chelating systems. Radiochimica Acta, 2007, 95, .	1.2	9

#	Article	IF	CITATIONS
559	Nuclear Localization of Factor Inhibitor Hypoxia-Inducible Factor in Prostate Cancer Is Associated With Poor Prognosis. Journal of Urology, 2011, 185, 1513-1518.	0.4	9
560	A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. British Journal of Cancer, 2018, 118, 770-776.	6.4	9
561	Novel humanized monoclonal antibodies for targeting hypoxic human tumors via two distinct extracellular domains of carbonic anhydrase IX. Cancer & Metabolism, 2022, 10, 3.	5.0	9
562	Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas. Clinical and Experimental Metastasis, 2000, 18, 313-319.	3.3	8
563	Automated uroâ€oncology data collection: the Cancer Research Uroâ€Oncology Database. BJU International, 2010, 105, 1663-1666.	2.5	8
564	Neoadjuvant Window Studies of Metformin and Biomarker Development for Drugs Targeting Cancer Metabolism. Journal of the National Cancer Institute Monographs, 2015, 2015, 81-86.	2.1	8
565	Elevated expression of the adhesion GPCR ADGRL4/ELTD1 promotes endothelial sprouting angiogenesis without activating canonical GPCR signalling. Scientific Reports, 2021, 11, 8870.	3.3	8
566	Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer. British Journal of Cancer, 2021, 125, 534-546.	6.4	8
567	Amifostine Protects Mouse Liver Against Radiation-induced Autophagy Blockage. Anticancer Research, 2018, 38, 227-238.	1.1	8
568	Plasma prostaglandins in lung cancer. European Journal of Cancer & Clinical Oncology, 1988, 24, 1069-1071.	0.7	7
569	Molecular Oncology and the Neoadjuvant Setting: the Perfect Blend for Treatment Personalization and Clinical Trial Design. Journal of the National Cancer Institute Monographs, 2011, 2011, 67-70.	2.1	7
570	ADGRL4/ELTD1 is a highly conserved angiogenesis-associated orphan adhesion GPCR that emerged with the first vertebrates and comprises 3 evolutionary variants. BMC Evolutionary Biology, 2019, 19, 143.	3.2	7
571	Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer. Oncotarget, 2017, 8, 78870-78881.	1.8	7
572	Comprehensive Imaging Characterization of Colorectal Liver Metastases. Frontiers in Oncology, 2021, 11, 730854.	2.8	7
573	False-positive ketonuria during ifosfamide and mesna therapy. European Journal of Cancer & Clinical Oncology, 1986, 22, 229-230.	0.7	6
574	Neoplastic stroma and epithelium show up-regulation of platelet-derived endothelial cell growth factor/thymidine phosphorylase in colorectal carcinomas but not adenomas. Angiogenesis, 1998, 2, 49-55.	7.2	6
575	Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1Â and Relation to Clinical Response. Journal of the National Cancer Institute Monographs, 2015, 2015, 64-66.	2.1	6
576	Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 137-153.	1.6	6

#	Article	IF	CITATIONS
577	Expression of VEGF in routinely fixed material using a new monoclonal. Journal of Pathology, 1998, 186, 313-318.	4.5	6
578	ELTD1 Activation Induces an Endothelial-EMT Transition to a Myofibroblast Phenotype. International Journal of Molecular Sciences, 2021, 22, 11293.	4.1	6
579	Liver glycogen phosphorylase is upregulated in glioblastoma and provides a metabolic vulnerability to high dose radiation. Cell Death and Disease, 2022, 13, .	6.3	6
580	Molecular profiling of signalling proteins for effects induced by the anti-cancer compound GSAO with 400 antibodies. BMC Cancer, 2006, 6, 155.	2.6	5
581	Metabolic compartments in tumor tissue: Implications for therapy. Cell Cycle, 2012, 11, 13-13.	2.6	5
582	Endogenous miRNA sponges mediate the generation of oscillatory dynamics for a non-coding RNA network. Journal of Theoretical Biology, 2019, 481, 54-60.	1.7	5
583	Differential effects of HIF2α antagonist and HIF2α silencing in renal cancer and sensitivity to repurposed drugs. BMC Cancer, 2021, 21, 896.	2.6	5
584	Tumour subregion analysis of colorectal liver metastases using semi-automated clustering based on DCE-MRI: Comparison with histological subregions and impact on pharmacokinetic parameter analysis. European Journal of Radiology, 2020, 126, 108934.	2.6	5
585	Investigations on Zinc Isotope Fractionation in Breast Cancer Tissue Using in vitro Cell Culture Uptake-Efflux Experiments. Frontiers in Medicine, 2021, 8, 746532.	2.6	5
586	Role of Hypoxia in the Interferon Response. Frontiers in Immunology, 2022, 13, 821816.	4.8	5
587	Partial Breast Reconstruction with Lateral Chest Wall Perforator Flap to Facilitate Breast Conservation in Breast Cancer: First 100 Cases with Cancer Outcomes at 8 Years Follow-Up and the Lessons Learned. Cancer Management and Research, 2021, Volume 13, 9453-9466.	1.9	5
588	Bleomycin and X-ray-hypersensitive Chinese hamster ovary cell mutants: Genetic analysis and cross-resistance to neocarzinostatin. Mutation Research - DNA Repair Reports, 1988, 193, 157-165.	1.8	4
589	When Cancer Co-opts the Vasculature. New England Journal of Medicine, 2014, 370, 2146-2147.	27.0	4
590	ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression. Molecular Cancer Research, 2021, 19, 1957-1969.	3.4	4
591	Blood vessel invasion and other variables as predictors of long-term survival in Japanese and British patients with primary invasive breast cancer. International Journal of Clinical and Experimental Pathology, 2014, 7, 7967-78.	0.5	4
592	Characterising 18F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging. British Journal of Cancer, 2022, 126, 598-605.	6.4	4
593	von Hippel-Lindau Syndrome: Target for Anti-Vascular Endothelial Growth Factor (VEGF) Receptor Therapy. Oncologist, 2000, 5, 32-36.	3.7	4
594	An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease. Cancer Chemotherapy and Pharmacology, 1995, 37, 134-138.	2.3	4

#	Article	IF	CITATIONS
595	Chemotherapy induced emesis may exacerbate the nephrotoxicity of combined ifosfamide/mesna and cisplatin chemotherapy. European Journal of Cancer & Clinical Oncology, 1989, 25, 917-918.	0.7	3
596	Growth factors and receptors in cancer. Current Opinion in Biotechnology, 1991, 2, 260-268.	6.6	3
597	Microenvironmental Induced Essentiality of Autophagy. Clinical Cancer Research, 2013, 19, 2791-2793.	7.0	3
598	Does Amifostine Reduce Metabolic Rate? Effect of the Drug on Gas Exchange and Acute Ventilatory Hypoxic Response in Humans. Pharmaceuticals, 2015, 8, 186-195.	3.8	3
599	Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumab. EJNMMI Research, 2017, 7, 49.	2.5	3
600	Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor initiating cells. JCI Insight, 2021, 6, .	5.0	3
601	Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. Journal of Pathology, 2000, 190, 430-436.	4.5	3
602	URINARY VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS CORRELATION WITH BLADDER CANCER RECURRENCE RATES. Journal of Urology, 1999, , 799-804.	0.4	3
603	Hypoxia signalling in tumour angiogenesis. Expert Opinion on Therapeutic Targets, 2000, 4, 361-375.	1.0	2
604	Measurement of Microvessel Density in Primary Tumors. , 2001, 57, 115-121.		2
605	Emerging therapeutic targets in angiogenesis. Expert Opinion on Therapeutic Targets, 1998, 2, 213-229.	1.0	1
606	Self assessment of health status and symptoms by cancer patients. International Journal of Pharmacy Practice, 2011, 2, 147-151.	0.6	1
607	Inhibitors of Tumor Angiogenesis. , 2014, , 275-317.		1
608	Unlocking the complexity of hypoxia non-coding transcriptome landscape of breast cancer. BMC Genomics, 2014, 15, .	2.8	1
609	ATF4, Hypoxia and Treatment Resistance in Cancer. Cancer Drug Discovery and Development, 2019, , 75-108.	0.4	1
610	Clinical strategies to inhibit tumor vascularization. , 2020, , 147-176.		1
611	Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. , 1999, 85, 1996.		1
612	Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. , 2000, 190, 430.		1

35

#	Article	IF	CITATIONS
613	The Tumor Microenvironment: New Insights into Regulation of Tumor pH by Carbonic Anhydrases. , 2010, , 23-41.		1
614	Diagnostic and Prognostic Significance of Tumor Angiogenesis. , 2002, , 151-176.		1
615	ROLE OF THYMIDINE PHOSPHORYLASE IN AN IN VITRO MODEL OF HUMAN BLADDER CANCER INVASION. Journal of Urology, 2002, , 1482-1486.	0.4	1
616	The driver landscape of angiosarcoma Journal of Clinical Oncology, 2014, 32, 10511-10511.	1.6	1
617	To branch or to expand?. ELife, 2016, 5, .	6.0	1
618	Assessment of renal toxicity by urinary enzymes in patients receiving chemotherapy with 8-methyl-8-acetylenic-putrescine. Cancer Chemotherapy and Pharmacology, 1990, 26, 65-66.	2.3	0
619	Introduction on Angiogenesis in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2005, 10, 281-282.	2.7	Ο
620	Inhibitors of tumor angiogenesis. , 2008, , 351-381.		0
621	Response: Re: Delta-Like Ligand 4-Notch Blockade and Tumor Radiation Response. Journal of the National Cancer Institute, 2012, 104, 421-422.	6.3	Ο
622	Changing prognosis of renal cell carcinoma: a single-centre experience over 25 years. Journal of Clinical Urology, 2013, 6, 119-124.	0.1	0
623	Functional comparison of Notch ligands in tumour angiogenesis. Asian Pacific Journal of Tropical Disease, 2014, 4, 229.	0.5	Ο
624	The Centromeric Protein, CEN(P)-F, a Marker of Cell Proliferation Is Regulated by Hypoxia in Human Mesenchymal Stem Cells and Their Bone Marrow Stromal Progeny Blood, 2005, 106, 1385-1385.	1.4	0
625	Carbonic anhydrase IX unifies spatial pH <sub>i</sub> regulation in large cellâ€clusters. FASEB Journal, 2007, 21, A926.	0.5	Ο
626	In vivo assessment of Delta likeâ€4 function in tumour development. FASEB Journal, 2007, 21, A16.	0.5	0
627	Hypoxic Regulation of Angiogenesis by HIF-1. , 2008, , 169-179.		0
628	Anoxia. , 2011, , 193-198.		0
629	Diagnostic and Prognostic Cancer Biomarkers: From Traditional to Systems Approaches. , 2011, , 329-366.		0
630	Atf4. The AFCS-nature Molecule Pages, 0, , .	0.2	0

#	Article	IF	CITATIONS
631	Clinical Exploitation of Hypoxia. Cancer Drug Discovery and Development, 2014, , 343-359.	0.4	О
632	Angiogenic Polypeptides in Breast Cancer: Expression of Mrna's in Primary Human Tumours, MCF-7 Cell Transfection and Xenograft Models. , 1998, , 213-221.		0
633	Anoxia. , 2015, , 249-258.		0
634	Anoxia., 2015, , 1-11.		0
635	Bioinformatic approaches elucidate a high likelyhood of interaction between miR-182 and the pro-apoptotic gene MTCH2 in breast cancers Journal of Clinical Oncology, 2015, 33, e12551-e12551.	1.6	0
636	Biological Therapies for Metastatic Breast Cancer: Antiangiogenesis. , 2006, , 671-704.		0
637	Abstract 5813: Glycogen synthesis as potential novel target in triple negative breast cancer: Glycogen synthase 1 expression in human breast cancers and the impact of downregulation on proliferation of preclinical models. Cancer Research, 2022, 82, 5813-5813	0.9	0